Traditionally, the therapeutic regimens of breast cancer clinically are developed mainly based on tumor size, pathological type, lymph node metastasis, etc. Along with the accumulation of genomic analysis and clinical data, it provides a new direction to formulate different treatment regimens according to the different expression of HER-2 in breast cancer patients.12 This evidence concerns the gene ERBB2 and breast carcinoma.